Palexia 100 mg film-coated tablets *

  • Company:

    Grunenthal Pharma Ltd.
  • Status:

    Updated
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 13 October 2021

File name

ie_leaflet-palexia 100mg fct approved v2.0 clean_1634151236.pdf

Reasons for updating

  • New PIL for medicines.ie

Free text change information supplied by the pharmaceutical company

Aligning this PIL to the EU texts - Approved. 

Updated on 08 June 2021

File name

m1-3-1-leaflet-pa-2242-12-3-v12-clean_1623142039.pdf

Reasons for updating

  • Change to section 2 - pregnancy, breast feeding and fertility
  • Change to section 4 - how to report a side effect

Updated on 08 June 2021

File name

m1-3-1-spc-2242-12-3-v11-clean_1623141991.pdf

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 14 July 2020

File name

m1-3-1-leaflet-pa-2242-12-3-v11-ipha_1594742722.pdf

Reasons for updating

  • Change to further information section

Free text change information supplied by the pharmaceutical company

Name change of product in Germany (Section 6 update)

Updated on 05 March 2020

File name

m1-3-1-leaflet-pa-2242-12-3-v10-ipha_1583409408.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Free text change information supplied by the pharmaceutical company

Information added on sleep-related breathing disorders

Updated on 05 March 2020

File name

m1-3-1-spc-2242-12-3-v10-clean_1583409217.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Information added on sleep-related breathing disorders

Updated on 31 October 2019

File name

m1-3-1-spc-2242-12-3-v9-clean-ipha_1572533598.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8:

Added Delirium** as an adverse event of unknown frequency

** Post marketing cases of delirium were observed in patients with additional risk factors such as cancer and advanced age.

Updated on 31 October 2019

File name

m1-3-1-leaflet-pa-2242-12-3-v9-ipha_1572532803.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 4:

Addition of Delirium as an adverse event of unknown frequency

Updated on 20 December 2018

File name

m1-3-1-leaflet-pa-2242-12-3-v8-ipha_1545258925.pdf

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink

Updated on 19 December 2018

File name

m1-3-1-spc-2242-12-3-v8-clean_1545258005.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4

Text added on Risk from concomitant use of sedating medicinal products such as benzodiazepines or related substances.

Section 4.5

Text updated in line with CMDh recommendation on ‘Sedative medicines such as benzodiazepines or related drugs’

Updated on 05 November 2018

File name

m1-3-1-leaflet-pa-2242-12-3-v7-ipha_1541424421.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 6 - date of revision

Updated on 05 November 2018

File name

m1-3-1-spc-2242-12-3-v7-clean_1541418486.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.4: Special warnings and precautions

Seizures: The following is included 'In addition, tapentadol may increase the  seizure risk in patients taking other medicinal products that lower the seizure threshold (see section 4.5)'

 Section 4.5: Interaction with other medicinal products and other forms of interaction

The following changes made:

​​PALEXIA can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other medicinal products that lower the seizure threshold to cause convulsions.

In isolated cases there have been reports of serotonin syndrome in a temporal connection with the therapeutic use of tapentadol in combination with serotinergic medicinal products such as selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants. Signs of serotonin syndrome may be for example confusion, agitation, fever, sweating, ataxia, hyperreflexia, myoclonus and diarrhea. Serotonin syndrome is likely when one of the following is observed:

  • Spontaneous clonus
  • Inducible or ocular clonus with agitation or diaphoresis
  • Tremor and hyperreflexia
  • Hypertonia and body temperature > 38oC and inducible ocular clonus

File name

m1-3-1-leaflet-pa-1189-7-3-v6-clean.pdf

Updated on 30 May 2018

File name

m1-3-1-spc-1189-7-3-v6-clean.docx

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

update to marketing authorisation holder and product authorisation number

Updated on 18 May 2018

File name

m1-3-1-leaflet-pa-1189-7-3-v6-clean.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 09 December 2016

Reasons for updating

  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 09 December 2016

File name

PIL_14969_86.pdf

Reasons for updating

  • New PIL for new product

Updated on 07 September 2016

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 07 September 2016

Reasons for updating

  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

  • Update to SPC following renewal of the marketing authorisation
  • In section 10, data of revision of text added

Updated on 16 December 2013

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 16 December 2013

Reasons for updating

  • Product/presentation re-marketed

Updated on 28 April 2011

Reasons for updating

  • New PIL for new product
  • PIL Submitted in error